Let's see how things develop.
Seasoned traders who understand risk could nibble on the long side of ALDX.
The shares have taken off and we have new price targets.
Two of the three members of this trio already have announced positive news developments that have given their shares big lifts.
Once M&A activity picks up, I could see the biotech sector easily rallying 20% or more.
Here's our trading strategy for the shares.
Let's take a look at the charts and indicators.
The technical signals of the genome editing company are largely bearish and indicate its stock is poised to weaken.
The government is turning on the flow of money to biotech at a time when the Fed is reducing the flow of money to the economy.